Asia Pacific pharmacovigilance and drug safety software market will grow by 8.9% annually with a total addressable market cap of $817.5 million over 2022-2031, driven by the increasing prevalence of chronic diseases due to the aging population, the growing drug discovery pipelines, increase in incidence of adverse drug reactions (ADR), more stringent regulatory guidelines for drug safety, and the increasing adoption of AI and cloud technologies in PV software and solutions.
Highlighted with 30 tables and 59 figures, this 117-page report 鈥淎sia Pacific Pharmacovigilance and Drug Safety Software 麻豆原创 2021-2031 by Functionality (Adverse Event Reporting, Drug Safety Audits, Issue Tracking, Fully Integrated), Clinical Phase (Pre-clinical, Phase I-IV), Method, Delivery Mode (On-premise, On-demand), Indication, End User (Pharma and Biotech Companies, CROs, BPOs, Others), and Country: Trend Forecast and Growth Opportunity鈥� is based on a comprehensive research of the entire Asia Pacific pharmacovigilance and drug safety software market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2018-2021 and provides forecast from 2022 till 2031 with 2021 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
鈥� 麻豆原创 Structure
鈥� Growth Drivers
鈥� Restraints and Challenges
鈥� Emerging Product Trends & 麻豆原创 Opportunities
鈥� Porter鈥檚 Fiver Forces
The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19 and Russia-Ukraine conflict. The balanced (most likely) projection is used to quantify Asia Pacific pharmacovigilance and drug safety software market in every aspect of the classification from perspectives of Functionality, Clinical Phase, Method, Delivery Mode, Indication, End User, and Country.
Based on Functionality, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
鈥� Adverse Event Reporting Software
鈥� Drug Safety Audits Software
鈥� Issue Tracking Software
鈥� Fully Integrated Software
Based on Clinical Phase, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
鈥� Pre-clinical
鈥� Phase I
鈥� Phase II
鈥� Phase III
鈥� Phase IV
By Method, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
鈥� Spontaneous Reporting
鈥� Intensified ADR Reporting
鈥� Targeted Spontaneous Reporting
鈥� Cohort Event Monitoring
鈥� EHR Mining
By Delivery Mode, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
鈥� On-premise Delivery
鈥� On-demand Delivery
By Indication, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
鈥� Oncology
鈥� Respiratory Disorders
鈥� Cardiology
鈥� Neurology
鈥� Immunology
鈥� Pain Management
鈥� Other Indications
By End Users, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
鈥� Pharmaceutical and Biotechnology Companies
鈥� Contract Research Organizations (CROs)
鈥� Business Process Outsourcing Firms (BPOs)
鈥� Other End Users
Geographically, the following national/local markets are fully investigated:
鈥� Japan
鈥� China
鈥� South Korea
鈥� Australia
鈥� India
鈥� Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)
For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2021-2031. The breakdown of national markets by Functionality, Delivery Mode and End User over the forecast years are also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Selected Key Players:
Ab Cube
Accenture PLC
ArisAsia Pacific LLC
Cognizant Technology Solutions Corporation
Ennov Solutions Inc.
Extedo GmbH
Honeywell International Inc. (Sparta Systems Inc.)
IQVIA Inc.
Max Application
Oracle Corporation
Sarjen Systems Pvt. Ltd.
United BioSource LLC
Veeva Systems Inc.
Wipro Limited
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
1 Introduction 8
1.1 Industry Definition and Research Scope 8
1.1.1 Industry Definition 8
1.1.2 Research Scope 9
1.2 Research Methodology 12
1.2.1 Overview of 麻豆原创 Research Methodology 12
1.2.2 麻豆原创 Assumption 13
1.2.3 Secondary Data 13
1.2.4 Primary Data 13
1.2.5 Data Filtration and Model Design 14
1.2.6 麻豆原创 Size/Share Estimation 15
1.2.7 Research Limitations 16
1.3 Executive Summary 17
2 麻豆原创 Overview and Dynamics 20
2.1 麻豆原创 Size and Forecast 20
2.1.1 Impact of COVID-19 on World Economy 21
2.1.2 Impact of COVID-19 on the 麻豆原创 25
2.2 Major Growth Drivers 27
2.3 麻豆原创 Restraints and Challenges 32
2.4 Emerging Opportunities and 麻豆原创 Trends 35
2.5 Porter鈥檚 Fiver Forces Analysis 39
3 Segmentation of Asia Pacific 麻豆原创 by Functionality 43
3.1 麻豆原创 Overview by Functionality 43
3.2 Adverse Event Reporting Software 45
3.3 Drug Safety Audits Software 46
3.4 Issue Tracking Software 47
3.5 Fully Integrated Software 48
4 Segmentation of Asia Pacific 麻豆原创 by Clinical Phase 49
4.1 麻豆原创 Overview by Clinical Phase 49
4.2 Pre-clinical 51
4.3 Phase I 52
4.4 Phase II 53
4.5 Phase III 54
4.6 Phase IV 55
5 Segmentation of Asia Pacific 麻豆原创 by Method 56
5.1 麻豆原创 Overview by Method 56
5.2 Spontaneous Reporting 58
5.3 Intensified ADR Reporting 59
5.4 Targeted Spontaneous Reporting 60
5.5 Cohort Event Monitoring 61
5.6 EHR Mining 62
6 Segmentation of Asia Pacific 麻豆原创 by Delivery Mode 63
6.1 麻豆原创 Overview by Delivery Mode 63
6.2 On-premise Delivery 65
6.3 On-demand Delivery 66
7 Segmentation of Asia Pacific 麻豆原创 by Indication 67
7.1 麻豆原创 Overview by Indication 67
7.2 Oncology 69
7.3 Respiratory Disorders 70
7.4 Cardiology 71
7.5 Neurology 72
7.6 Immunology 73
7.7 Pain Management 74
7.8 Other Indications 75
8 Segmentation of Asia Pacific 麻豆原创 by End User 76
8.1 麻豆原创 Overview by End User 76
8.2 Pharmaceutical and Biotechnology Companies 78
8.3 Contract Research Organizations (CROs) 79
8.4 Business Process Outsourcing Firms (BPOs) 80
8.5 Other End Users 81
9 Asia-Pacific 麻豆原创 2021-2031 by Country 82
9.1 Overview of Asia-Pacific 麻豆原创 82
9.2 Japan 85
9.3 China 88
9.4 Australia 90
9.5 India 92
9.6 South Korea 94
9.7 Rest of APAC Region 96
10 Competitive Landscape 98
10.1 Overview of Key Vendors 98
10.2 New Product Launch, Partnership, Investment, and M&A 101
10.3 Company Profiles 102
Ab Cube 102
Accenture PLC 104
ArisAsia Pacific LLC 105
Cognizant Technology Solutions Corporation 106
Ennov Solutions Inc. 107
Extedo GmbH 108
Honeywell International Inc. (Sparta Systems Inc.) 109
IQVIA Inc. 110
Max Application 111
Oracle Corporation 112
Sarjen Systems Pvt. Ltd. 113
United BioSource LLC 114
Veeva Systems Inc. 115
Wipro Limited 116
RELATED REPORTS 117
Selected Key Players:
Ab Cube
Accenture PLC
ArisGlobal LLC
Cognizant Technology Solutions Corporation
Ennov Solutions Inc.
Extedo GmbH
Honeywell International Inc. (Sparta Systems Inc.)
IQVIA Inc.
Max Application
Oracle Corporation
Sarjen Systems Pvt. Ltd.
United BioSource LLC
Veeva Systems Inc.
Wipro Limited
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
听
听
*If Applicable.
